Related Experiment Video
Updated: May 28, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Antiplatelet agents for the treatment and prevention of atherothrombosis
Carlo Patrono1, Felicita Andreotti, Harald Arnesen
1Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. carlo.patrono@rm.unicatt.it
European Heart Journal
|October 25, 2011
Summary
This review provides updated guidance on antiplatelet drug strategies for preventing and treating atherothrombosis. It aims to help physicians select optimal antiplatelet therapy for individual patients based on risk and clinical presentation.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Background:
- Previous reviews by the European Society of Cardiology (ESC) and American College of Chest Physicians (ACCP) have addressed antiplatelet drug clinical pharmacology.
- Collaborative meta-analyses of 287 secondary and 6 primary prevention trials offer insights into antiplatelet drug efficacy and safety in atherothrombosis.
Purpose of the Study:
- To provide an updated instrument for practicing physicians.
- To guide the selection of optimal antiplatelet strategies for individual patients.
- To address patients at risk or with clinical manifestations of atherothrombosis.
Main Methods:
- Review of existing clinical pharmacology data on antiplatelet drugs.
- Synthesis of evidence from meta-analyses of primary and secondary prevention trials.
- Development of updated clinical guidance for physicians.
Main Results:
- The document consolidates information on antiplatelet drug efficacy and safety.
- It offers a framework for tailoring antiplatelet therapy.
- It addresses the complexities of managing atherothrombosis.
Conclusions:
- An updated antiplatelet strategy is crucial for managing patients with atherothrombosis.
- Physician guidance is essential for selecting appropriate antiplatelet therapy.
- Individualized treatment based on patient risk and presentation is recommended.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...